Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence

Lung Cancer

Volumn 71, Issue 3, 2011, Pages 249-257

  Gridelli, C ^a   De Marinis, F ^b   Di Maio, M ^c   Cortinovis, D ^d   Cappuzzo, F ^e   Mok, T ^f  

^a S G MOSCATI HOSPITAL   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e Civil Hospital   (Italy)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Advanced NSCLC; EGFR mutation; First line treatment; Gefitinib

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; PACLITAXEL;

ADVANCED CANCER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG TOLERABILITY; DRY SKIN; FATIGUE; GENE MUTATION; HAIR LOSS; HUMAN; HYPERTRANSAMINASEMIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; VOMITING;

EID: 79851511500     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.12.008     Document Type: Review

References (44)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
2. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 9:183-232.
3. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21:2237-2246.
4. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
5. Cohen M.H., Williams G.A., Sridhara R., Chen G., McGuinn W.D., Morse D., et al. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839, Iressa) tablets. Clin Cancer Res 2004, 10:1212-1218.
6. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung cancer). Lancet 2005, 366:1527-1537.
7. Blackhall F., Ranson M., Thatcher N. Where next for gefitinib in patients with lung cancer?. Lancet Oncol 2006, 7:499-507.
8. Cufer T., Vrdoljak E., Gaafar R., Erensoy I., Pemberton K. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006, 17:401-409. SIGN Study Group.
9. Lee D., Kim S., Park K., Kim J., Lee J., Shin S., et al. A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy. J Clin Oncol 2008, 26(May 20 suppl.). [abstract 8025].
10. Maruyama R., Nishiwaki Y., Tamura T., Yamamoto N., Tsuboi M., Nakagawa K., et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008, 26:4244-4252.
11. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-smallcell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
12. Shepherd F.A., Douillard J., Fukuoka M., Saijo N., Kim S., Cufer T., et al. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): meta-analysis from four clinical trials. J Clin Oncol 2009, 27(15s). (suppl; abstr 8011).
13. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004, 22:777-784.
14. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004, 22:785-794.
15. Reck M., Buchholz E., Romer K.S., Krutzfeldt K., Gatzemeier U., Manegold C. Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer. Clin Lung Cancer 2006, 7:406-411.
16. Niho S., Kubota K., Goto K., Yoh K., Ohmatsu H., Kakinuma R., et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 2006, 24:64-69.
17. Crinò L., Cappuzzo F., Zatloukal P., Reck M., Pesek M., Thompson J.C., et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008, 26:4253-4260.
18. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
19. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
20. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
21. Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004, 10:8195-8203.
22. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
23. Asahina H., Yamazaki K., Kinoshita I., Sukoh N., Harada M., Yokouchi H., et al. A phase II trial of gefitinib as first-line therapy for advanced nonsmall cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006, 95:998-1004.
24. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006, 24:3340-3346.
25. Sutani A., Nagai Y., Udagawa K., Uchida Y., Koyama N., Murayama Y., et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 2006, 95:1483-1489.
26. Tamura K., Okamoto I., Kashii T., Negoro S., Hirashima T., Kudoh S., et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008, 98:907-914.
27. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Jänne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449. [Erratum in: J Clin Oncol 26:3472].
28. Lee D.H., Han J.Y., Yu S.Y., Kim H.Y., Nam B.H., Hong E.K., et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol 2006, 1:965-971.
29. Cappuzzo F., Ligorio C., Jänne P.A., Toschi L., Rossi E., Trisolini R., et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization positive/phospho-akt-positive or never smoker patients with advanced non-small-cell lung cancer: The ONCOBELL Trial. J Clin Oncol 2007, 25:2248-2255.
30. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
31. Lee J.S., Park K., Kim S.W., Lee D.H., Kim H.T., Han J.Y., et al. Presented at World Conference on Lung Cancer. A randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung 2009, [abstractact PRS.4].
32. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
33. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
34. Yang C.H., Fukuoka M., Mok T.S., Wu Y.L., Thongprasert S., Saijo N., et al. Final overall survival results from a phase III, randomised, open-label, first-line study of gefitinib vs. carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). Presented at European Society of Medical Oncology meeting 2010, [abstract LBA2].
35. Fukuoka M., Wu Y., Thongprasert S., Yang C., Chu D., Saijo N., et al. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). J Clin Oncol 2009, 27(15s). (suppl; abstr 8006).
36. Di Maio M., Gallo C., De Maio E., Morabito A., Piccirillo M.C., Gridelli C., et al. Methodological aspects of lung cancer clinical trials in the era of targeted agents. Lung Cancer 2010, 67:127-135.
37. Douillard J.Y., Shepherd F.A., Hirsh V., Mok T., Socinski M.A., Gervais R., et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744-752.
38. Mok T., To K.F., Wu Y.L., Thongprasert S., Yang C.H., Saijo N., et al. Clinical outcomes of patients with different types of epidermal growth factor receptor mutations in IPASS. Presented at World Conference on Lung Cancer 2009, [abstract B9.5].
39. Godin-Heymann N., Ulkus L., Brannigan B.W., McDermott U., Lamb J., Maheswaran S., et al. The T790M 'gatekeeper' mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 2008, 7:874-879.
40. Mok T.S. Living with imperfection. J Clin Oncol 2010, 28:191-192.
41. Zhou C., Wung Y.I., Chen G., Feng J., Liu X., Wang C., et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in chinese advanced non-small-cell lung cancer patients with EGFR activating mutations. Presented at European Society of Medical Oncology (ESMO) Congress 2010, [abstract LBA13].
42. Miller V.A., Hirsh V., Cadranel J., Chen Y.M., Park K., Kim S.W., et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). Presented at European Society of Medical Oncology (ESMO) Congress 2010, [abstractact LBA1].
43. Yang C., Shih J., Su W., Hsia T., Tsai C., Ou S.I., et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). J Clin Oncol 2010, 28(15s). (suppl; abstr 7521).
44. Di Maio M., Morabito A., Piccirillo M.C., Daniele G., Giordano P., Costanzo R., et al. New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. Expert Opin Investig Drugs 2010, 19:1503-1514.